SCHEMBL4377423

SCHEMBL4377423

C=CCN1CCN(C(=O)C=Cc2ccc(N(C)C)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 7/20 0.57
HSD17B3 P37058 1/20 0.52
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 1/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
GAA P10253 1/20 0.47
CCR2 P41597 1/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
BCHE P06276 1/20 0.45
MAOA P21397 1/20 0.45
ACHE P22303 1/20 0.45
MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13636161 1.00 GPR183 (0.57) GPR183HSD17B3ALDH1A1SMN1; SMN2MAPT
SCHEMBL14218064 0.86 GPR183 (0.71) GPR183HSD17B3ALDH1A1SMN1; SMN2MAPT
SCHEMBL1612931 0.79 HSD17B3 (0.61) GPR183HSD17B3ALDH1A1SMN1; SMN2MAPT
SCHEMBL1612928 0.79 HSD17B3 (0.61) GPR183HSD17B3ALDH1A1SMN1; SMN2MAPT
SCHEMBL13636003 0.75 GPR183 (0.57) GPR183HSD17B3ALDH1A1SMN1; SMN2MAPT
SCHEMBL4381758 0.75 GPR183 (0.57) GPR183ALDH1A1TDP1ACHE
SCHEMBL4380647 0.75 GPR183 (0.57) GPR183HSD17B3ALDH1A1SMN1; SMN2MAPT
SCHEMBL14190945 0.75 GPR183 (0.57) GPR183ALDH1A1TDP1ACHE
SCHEMBL4385749 0.74 GPR183 (0.56) GPR183HSD17B3ALDH1A1SMN1; SMN2MAPT
SCHEMBL13636194 0.74 GPR183 (0.56) GPR183HSD17B3SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 GPR183 264/4885HSD17B3 1349/4885ALDH1A1 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.